By Robb M. Stewart

 

Appili Therapeutics Inc.'s shares climbed Wednesday after the biopharmaceutical company said its new drug application for a liquid oral reformulation of the antibiotic metronidazole was accepted by the U.S. Food and Drug Administration.

In morning trading, the shares were up 10% at C$0.06, extending the run higher so far this year to 22%.

The FDA's acceptance of the application for ATI-1501, which has been licensed to Saptalis Pharmaceuticals LLC, is a step toward bringing the drug to market. The agency has set a Prescription Drug User Fee action data of Sept. 23, Appili said.

The company said it is working with New York-based Saptalis on supporting the review process and responding to questions from the FDA.

 

Write to Robb M. Stewart at robb.stewart@wsj.com

 

(END) Dow Jones Newswires

February 08, 2023 11:16 ET (16:16 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Appili Therapeutics Charts.
Appili Therapeutics (TSX:APLI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Appili Therapeutics Charts.